FindTrial
Sign In

Recurrence rate in patients with moderate to severe Hidradenitis Suppurativa treated with Xeligekimab: a multicenter, prospective, observational clinical study

Recurrence rate in patients with moderate to severe Hidradenitis Suppurativa treated with Xeligekimab: a multicenter, prospective, observational clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101115
Enrollment
Unknown
Registered
2025-04-21
Start date
2025-05-05
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hidradenitis Suppurativa

Interventions

Observation group:None

Sponsors

Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Participated in another clinical trial "Efficacy and safety evaluation of sericilimumab in the treatment of hidradenitis suppurativa: a multi-center, randomized, double-blind, placebo-controlled clinical trial"; 2. Received at least 8 weeks of treatment with sericilimumab; 3. Sign the Informed consent form.

Exclusion criteria

Exclusion criteria: 1. Any other active skin disease that may interfere with HS assessment; Including but not limited to: atopic dermatitis, psoriasis, pemphigus, systemic lupus erythematosus, urticaria, etc. 2. Unable to go to the hospital regularly for systemic skin examinations.

Design outcomes

Primary

MeasureTime frame
Recurrence rate;—

Secondary

MeasureTime frame
The influencing factors of recurrence;—

Countries

China

Contacts

Public ContactWenhui Wang

Peking University Third Hospital

wwh0608@126.com+86 186 1826 9457

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026